BIOM-34. CLINICAL, RADIOGRAPHIC, AND PATHOLOGIC PREDICTORS OF RESPONSE TO ANTI-PD-1 AND ANTI-PD-L1 THERAPY IN IDH-WILDTYPE GLIOBLASTOMA PATIENTS. (9th November 2020)

• Record Type: Journal Article
• Authors: Iorgulescu, Bryan; Lim-Fat, Mary Jane; Qin, Lei; Grant, Gareth; Huang, Raymond; Young, Geoffrey; Reardon, David
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 2
• Page Start: ii8
• Page End: ii9
• Publication Date: 2020-11-09
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa215.033
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Although monoclonal antibodies targeting PD-1 and its ligand PD-L1 have improved overall survival (OS) for many cancers, recent trials of anti-PD-(L)1 in glioblastoma revealed no OS benefit. However, a small subset of patients appears to benefit, warranting evaluation of predictive markers of improved survival. METHODS: We evaluated 108 patients managed at Dana-Farber Cancer Institute for IDH-wildtype glioblastoma, who received anti-PD-(L)1 therapy and had complete clinical, pathologic, and radiographic data. OS was measured from anti-PD-(L)1 initiation to death or censored at last follow-up. Predictors of OS were evaluated by multivariable Cox regression, adjusted for age at diagnosis, sex, disease setting (newly-diagnosed vs. recurrent), MGMT status, chemotherapy and bevacizumab before/during anti-PD-(L)1, extent of resection prior to anti-PD-(L)1, and, at anti-PD-(L)1 initiation: KPS, dexamethasone use, absolute lymphocyte count (ALC), ADC mean value, FLAIR volume, T1 post-contrast volume. RESULTS: Of 108 patients, 28 (25.9%) were newly-diagnosed, 80 (74.1%) were treated in the recurrent setting, and 100 died (92.3%). In multivariable analysis, unmethylated MGMT (HR 2.31, 95%CI: 1.38–3.88, p=0.002), and, at the time of anti-PD-(L)1 initiation, baseline dexamethasone use (HR 1.79, 95%CI: 1.07–3.00, p=0.03), lower ADC mean values (reference 2 nd quartile [1, 130-1, 262 10 -6 mm 2 /s]; 3 rd quartile [1, 268–1, 388] HR 0.32, 95%CI: 0.15–0.67, p=0.002; 4 th quartile [1, 402–11, 966] HR 0.30, 95%CI: 0.14–0.66, p=0.003), and higher T1 post-contrast volumes (reference 2 nd quartile [4, 121–8, 157mm 3 ]; 3 rd quartile [8, 701–14, 663mm 3 ] HR 2.08, 95%CI: 1.03–4.19, p=0.04; 4 th quartile [15, 566-64, 362mm 3 ] HR 3.15, 95%CI: 1.49–6.69, p=0.003) independently predicted worse OS. Older age (HR 1.02/year, 95%CI: 1.00–1.05, p=0.07) and lower ALC (HR 0.66/unit, 0.40–1.10, p=0.11) trended towards worse OS. CONCLUSION: Unmethylated MGMT, and, at the time of starting anti-PD-(L)1, baseline dexamethasone, low ADC mean value, and high T1 post-contrast volume may be predictive of worse OS in IDH-wildtype glioblastoma patients treated with anti-PD-(L)1. These findings may help better select patients who could benefit from PD-(L)1 inhibitors.